Home ›
Gastric Cancer Trials ›
NCT05177133
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously untreated metastatic or locally advanced esophagogastric cancer.
Trial Details
NCT ID NCT05177133
Phase PHASE2
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status RECRUITING
Cancer Type Gastric Cancer
Interventions Capecitabine Oxaliplatin Retifanlimab
Locations (sample) Amsterdam, Netherlands|52.37403,4.88969 Amsterdam, Netherlands|52.37403,4.88969 Eindhoven, Netherlands|51.44083,5.47778 Leeuwarden, Netherlands|53.20271,5.80973 Leiden, Netherlands|52.15833,4.49306
Key Eligibility Criteria
Patients must provide written informed consent according to ICH/GCP, and national/local regulations prior to any screening procedures. Male or female adult patients (≥ 18 years). Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or gastroesophageal junc… Patients with metastatic or irresectable adenocarcinoma of the stomach or oesophagus not pre-treated with chemotherapy or radiotherapy for irresect…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Gastric Cancer Trials on Trialify →